(MRK) Merck - Ratings and Ratios
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US58933Y1055
Oncology Vaccines Antimicrobials Diabetes Cardiovascular
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 3.70% |
| Yield on Cost 5y | 4.96% |
| Yield CAGR 5y | 5.58% |
| Payout Consistency | 97.7% |
| Payout Ratio | 37.9% |
| Risk via 5d forecast | |
|---|---|
| Volatility | 27.4% |
| Value at Risk 5%th | 40.4% |
| Relative Tail Risk | -10.35% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.58 |
| Alpha | 9.05 |
| CAGR/Max DD | 0.09 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.413 |
| Beta | 0.397 |
| Beta Downside | 0.361 |
| Drawdowns 3y | |
|---|---|
| Max DD | 43.44% |
| Mean DD | 16.14% |
| Median DD | 12.26% |
Description: MRK Merck December 01, 2025
Merck & Co. (NYSE: MRK) is a global, diversified healthcare firm that markets prescription medicines (e.g., Keytruda, Januvia/Janumet, Gardasil), veterinary pharmaceuticals, and animal-health vaccines, while also maintaining a pipeline of oncology collaborations (Daiichi Sankyo ADCs, AstraZeneca Lynparza, LaNova LM-299) and partnership agreements with firms such as Eisai, Bayer and Moderna.
Key performance indicators from the most recent fiscal year show total revenue of roughly $13.5 billion, with Keytruda contributing about $5.5 billion (≈ 41 % of sales) and an R&D spend of $5.6 billion (≈ 41 % of revenue). The company’s dividend yield sits near 3 % and its cash-flow conversion remains above 80 %, while the broader pharma sector benefits from an aging global population and accelerating adoption of immuno-oncology therapies-both of which support Merck’s growth outlook.
For a deeper quantitative assessment, you may find ValueRay’s analyst tools useful.
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income: 19.03b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.10 > 0.02 and ΔFCF/TA -2.55 > 1.0 |
| NWC/Revenue: 29.47% < 20% (prev 17.06%; Δ 12.41% < -1%) |
| CFO/TA 0.13 > 3% & CFO 17.07b > Net Income 19.03b |
| Net Debt (23.20b) to EBITDA (27.66b): 0.84 < 3 |
| Current Ratio: 1.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.50b) vs 12m ago -1.69% < -2% |
| Gross Margin: 77.18% > 18% (prev 0.76%; Δ 7642 % > 0.5%) |
| Asset Turnover: 52.00% > 50% (prev 53.75%; Δ -1.75% > 0%) |
| Interest Coverage Ratio: 18.14 > 6 (EBITDA TTM 27.66b / Interest Expense TTM 1.27b) |
Altman Z'' 4.96
| A: 0.15 (Total Current Assets 47.56b - Total Current Liabilities 28.63b) / Total Assets 129.55b |
| B: 0.56 (Retained Earnings 72.23b / Total Assets 129.55b) |
| C: 0.19 (EBIT TTM 23.09b / Avg Total Assets 123.54b) |
| D: 0.89 (Book Value of Equity 68.82b / Total Liabilities 77.64b) |
| Altman-Z'' Score: 4.96 = AAA |
Beneish M -3.00
| DSRI: 1.05 (Receivables 12.12b/11.38b, Revenue 64.23b/63.17b) |
| GMI: 0.98 (GM 77.18% / 75.82%) |
| AQI: 0.95 (AQ_t 0.43 / AQ_t-1 0.46) |
| SGI: 1.02 (Revenue 64.23b / 63.17b) |
| TATA: 0.02 (NI 19.03b - CFO 17.07b) / TA 129.55b) |
| Beneish M-Score: -3.00 = AA |
ValueRay F-Score (Strict, 0-100) 82.87
| 1. Piotroski: 5.50pt |
| 2. FCF Yield: 4.34% |
| 3. FCF Margin: 20.31% |
| 4. Debt/Equity: 0.80 |
| 5. Debt/Ebitda: 0.84 |
| 6. ROIC - WACC: 16.51% |
| 7. RoE: 38.95% |
| 8. Revenue Trend: 70.32% |
| 9. EPS Trend: 13.51% |
What is the price of MRK shares?
As of January 23, 2026, the stock is trading at USD 109.18 with a total of 9,362,579 shares traded.
Over the past week, the price has changed by -1.61%, over one month by +4.26%, over three months by +25.69% and over the past year by +18.40%.
Over the past week, the price has changed by -1.61%, over one month by +4.26%, over three months by +25.69% and over the past year by +18.40%.
Is MRK a buy, sell or hold?
Merck has received a consensus analysts rating of 4.04.
Therefore, it is recommended to buy MRK.
- Strong Buy: 12
- Buy: 3
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the MRK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 113.3 | 3.8% |
| Analysts Target Price | 113.3 | 3.8% |
| ValueRay Target Price | 116.2 | 6.4% |
MRK Fundamental Data Overview January 17, 2026
P/E Trailing = 14.6786
P/E Forward = 11.8064
P/S = 4.3151
P/B = 5.314
P/EG = 1.1693
Revenue TTM = 64.23b USD
EBIT TTM = 23.09b USD
EBITDA TTM = 27.66b USD
Long Term Debt = 39.97b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 41.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.20b USD (from netDebt column, last quarter)
Enterprise Value = 300.38b USD (277.18b + Debt 41.37b - CCE 18.17b)
Interest Coverage Ratio = 18.14 (Ebit TTM 23.09b / Interest Expense TTM 1.27b)
EV/FCF = 23.02x (Enterprise Value 300.38b / FCF TTM 13.05b)
FCF Yield = 4.34% (FCF TTM 13.05b / Enterprise Value 300.38b)
FCF Margin = 20.31% (FCF TTM 13.05b / Revenue TTM 64.23b)
Net Margin = 29.63% (Net Income TTM 19.03b / Revenue TTM 64.23b)
Gross Margin = 77.18% ((Revenue TTM 64.23b - Cost of Revenue TTM 14.66b) / Revenue TTM)
Gross Margin QoQ = 77.69% (prev 77.50%)
Tobins Q-Ratio = 2.32 (Enterprise Value 300.38b / Total Assets 129.55b)
Interest Expense / Debt = 0.79% (Interest Expense 327.0m / Debt 41.37b)
Taxrate = 14.20% (958.0m / 6.75b)
NOPAT = 19.81b (EBIT 23.09b * (1 - 14.20%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.85b)
Debt / EBITDA = 0.84 (Net Debt 23.20b / EBITDA 27.66b)
Debt / FCF = 1.78 (Net Debt 23.20b / FCF TTM 13.05b)
Total Stockholder Equity = 48.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.41% (Net Income 19.03b / Total Assets 129.55b)
RoE = 38.95% (Net Income TTM 19.03b / Total Stockholder Equity 48.87b)
RoCE = 25.99% (EBIT 23.09b / Capital Employed (Equity 48.87b + L.T.Debt 39.97b))
RoIC = 23.02% (NOPAT 19.81b / Invested Capital 86.06b)
WACC = 6.51% (E(277.18b)/V(318.55b) * Re(7.38%) + D(41.37b)/V(318.55b) * Rd(0.79%) * (1-Tc(0.14)))
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 84.35% ; FCFF base≈13.77b ; Y1≈14.41b ; Y5≈16.70b
Fair Price DCF = 156.6 (EV 411.88b - Net Debt 23.20b = Equity 388.68b / Shares 2.48b; r=6.51% [WACC]; 5y FCF grow 5.00% → 2.90% )
EPS Correlation: 13.51 | EPS CAGR: 10.08% | SUE: 3.25 | # QB: 3
Revenue Correlation: 70.32 | Revenue CAGR: 6.75% | SUE: 0.60 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.59 | Chg30d=-1.184 | Revisions Net=-2 | Analysts=9
EPS next Year (2026-12-31): EPS=7.01 | Chg30d=-1.411 | Revisions Net=-7 | Growth EPS=-21.7% | Growth Revenue=+4.9%
P/E Forward = 11.8064
P/S = 4.3151
P/B = 5.314
P/EG = 1.1693
Revenue TTM = 64.23b USD
EBIT TTM = 23.09b USD
EBITDA TTM = 27.66b USD
Long Term Debt = 39.97b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 41.37b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 23.20b USD (from netDebt column, last quarter)
Enterprise Value = 300.38b USD (277.18b + Debt 41.37b - CCE 18.17b)
Interest Coverage Ratio = 18.14 (Ebit TTM 23.09b / Interest Expense TTM 1.27b)
EV/FCF = 23.02x (Enterprise Value 300.38b / FCF TTM 13.05b)
FCF Yield = 4.34% (FCF TTM 13.05b / Enterprise Value 300.38b)
FCF Margin = 20.31% (FCF TTM 13.05b / Revenue TTM 64.23b)
Net Margin = 29.63% (Net Income TTM 19.03b / Revenue TTM 64.23b)
Gross Margin = 77.18% ((Revenue TTM 64.23b - Cost of Revenue TTM 14.66b) / Revenue TTM)
Gross Margin QoQ = 77.69% (prev 77.50%)
Tobins Q-Ratio = 2.32 (Enterprise Value 300.38b / Total Assets 129.55b)
Interest Expense / Debt = 0.79% (Interest Expense 327.0m / Debt 41.37b)
Taxrate = 14.20% (958.0m / 6.75b)
NOPAT = 19.81b (EBIT 23.09b * (1 - 14.20%))
Current Ratio = 1.66 (Total Current Assets 47.56b / Total Current Liabilities 28.63b)
Debt / Equity = 0.80 (Debt 41.37b / totalStockholderEquity, last quarter 51.85b)
Debt / EBITDA = 0.84 (Net Debt 23.20b / EBITDA 27.66b)
Debt / FCF = 1.78 (Net Debt 23.20b / FCF TTM 13.05b)
Total Stockholder Equity = 48.87b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.41% (Net Income 19.03b / Total Assets 129.55b)
RoE = 38.95% (Net Income TTM 19.03b / Total Stockholder Equity 48.87b)
RoCE = 25.99% (EBIT 23.09b / Capital Employed (Equity 48.87b + L.T.Debt 39.97b))
RoIC = 23.02% (NOPAT 19.81b / Invested Capital 86.06b)
WACC = 6.51% (E(277.18b)/V(318.55b) * Re(7.38%) + D(41.37b)/V(318.55b) * Rd(0.79%) * (1-Tc(0.14)))
Discount Rate = 7.38% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -1.11%
[DCF Debug] Terminal Value 84.35% ; FCFF base≈13.77b ; Y1≈14.41b ; Y5≈16.70b
Fair Price DCF = 156.6 (EV 411.88b - Net Debt 23.20b = Equity 388.68b / Shares 2.48b; r=6.51% [WACC]; 5y FCF grow 5.00% → 2.90% )
EPS Correlation: 13.51 | EPS CAGR: 10.08% | SUE: 3.25 | # QB: 3
Revenue Correlation: 70.32 | Revenue CAGR: 6.75% | SUE: 0.60 | # QB: 0
EPS next Quarter (2026-03-31): EPS=0.59 | Chg30d=-1.184 | Revisions Net=-2 | Analysts=9
EPS next Year (2026-12-31): EPS=7.01 | Chg30d=-1.411 | Revisions Net=-7 | Growth EPS=-21.7% | Growth Revenue=+4.9%
Additional Sources for MRK Stock
News:
Wall Street Journal |
Benzinga |
Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle